 |
|
Volume 9, Number 4 |
|
| Distal DVT: why do we anticoagulate? |
Peter Rose, Editor |
In the recent update of the third edition of the Guidelines on oral anticoagulation produced by the British Committee for Standards in Haematology (BCSH),1 the duration of anticoagulant therapy after a first episode of deep vein thrombosis (DVT) has again been considered. For calf vein thrombosis, the guidelines recommend a minimum of six weeks of therapy. |
|
| British Thoracic Society winter meeting 2005 |
Keith Rhodes Independent medical writer |
Some 1,800 clinicians and other medical professionals attended the winter meeting of the British Thoracic Society (BTS), which took place on 7–9 December at the Queen Elizabeth II Conference Centre in central London. |
|
| Non-compliance in patients on long-term oral anticoagulation treatment |
Teresa Tripp RN BSc Anticoagulation Clinical Nurse Specialist, John Radcliffe Hospital, Oxford |
Patients will not always behave in accordance with advice given to them by healthcare professionals.1 They may not take medication as prescribed, attend healthcare appointments or make lifestyle changes that have been recommended. For patients who have had or are at risk of having a thromboembolic event, it may seem obvious to healthcare professionals that patients should follow their evidence-based advice. |
|
| Guidelines for patient self-testing and management of oral anticoagulation |
David Fitzmaurice FRCGP MD Professor of Primary Care Research, The Medical School, University of Birmingham |
Guidelines for patient self-testing and management of oral anticoagulation to assist healthcare professionals were recently published in the British Journal of Haematology.1 This article summarises the practical points from the guidelines. |
|
| Thrombogenecity of thalidomide in myeloma |
Mahesh Kumar MBBS Haematology Senior House Officer, University Hospitals Coventry and Warwickshire; Shankaranarayana Paneesha MD MRCP MRCPath Haematology Clinical Research Fellow, Warwick Hospital; Anton Borg MD MRCP MRCPath Consultant Haematologist, Warwick Hospital |
Thalidomide, a synthetic derivative of glutamic acid, is an important recent addition to the treatment of various malignancies, including multiple myeloma. The antitumour effect of thalidomide is believed to occur through immunomodulation and anti-angiogenic effect. |
|
